Canada's Zymeworks agreed to partner with Merck & Co. to develop "bispecific" antibody drugs for cancer and autoimmune conditions. The deal entitles Zymeworks to as much as $187 million in upfront and milestone fees, plus tiered royalties. Merck will gain exclusive global rights to market resulting therapies.

Full Story:

Related Summaries